相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Camille Leonce et al.
MOLECULAR CANCER RESEARCH (2022)
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma
Lorey K. Smith et al.
NATURE COMMUNICATIONS (2022)
Optogenetic actuator - ERK biosensor circuits identify MAPK network nodes that shape ERK dynamics
Coralie Dessauges et al.
MOLECULAR SYSTEMS BIOLOGY (2022)
Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling
Bas Ponsioen et al.
NATURE CELL BIOLOGY (2021)
Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling
Chen Yang et al.
NATURE COMMUNICATIONS (2021)
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Neal S. Akhave et al.
CANCER DISCOVERY (2021)
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
D. Lucas Kerr et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2021)
Targeting Son of Sevenless 1: The pacemaker of KRAS
Dirk Kessler et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2021)
Collective ERK/Akt activity waves orchestrate epithelial homeostasis by driving apoptosis-induced survival
Paolo Armando Gagliardi et al.
DEVELOPMENTAL CELL (2021)
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Beike Wang et al.
ONCOGENE (2021)
E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma
Xiao Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation
Hee Won Yang et al.
ELIFE (2020)
Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics
Anatoly Kiyatkin et al.
SCIENCE SIGNALING (2020)
Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation
Shensi Shen et al.
CELL REPORTS (2020)
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells
Luca Gerosa et al.
CELL SYSTEMS (2020)
Non-genetic mechanisms of therapeutic resistance in cancer
Jean-Christophe Marine et al.
NATURE REVIEWS CANCER (2020)
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Victoria E. Wang et al.
CLINICAL CANCER RESEARCH (2019)
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Andrew M. Kidger et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model
Istvan Kenessey et al.
MELANOMA RESEARCH (2018)
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Carmine Fedele et al.
CANCER DISCOVERY (2018)
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Michael J. Vido et al.
CELL REPORTS (2018)
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition
Valentina Comunanza et al.
EMBO MOLECULAR MEDICINE (2017)
Rare cell variability and drug- induced reprogramming as a mode of cancer drug resistance
Sydney M. Shaffer et al.
NATURE (2017)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Yujie Zhao et al.
ONCOLOGIST (2015)
Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
Melanie Sweetlove et al.
FRONTIERS IN ONCOLOGY (2015)
Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
Curtis H. Kugel et al.
CANCER RESEARCH (2014)
High-Sensitivity Measurements of Multiple Kinase Activities in Live Single Cells
Sergi Regot et al.
CELL (2014)
Spatiotemporal Control of Fibroblast Growth Factor Receptor Signals by Blue Light
Nury Kim et al.
CHEMISTRY & BIOLOGY (2014)
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Amanda Lassen et al.
MOLECULAR CANCER (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long et al.
NATURE COMMUNICATIONS (2014)
PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
Francesco Sabbatino et al.
ONCOTARGET (2014)
The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit
Sabrina L. Spencer et al.
CELL (2013)
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Karen E. Sheppard et al.
CLINICAL CANCER RESEARCH (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Matthew A. Held et al.
CANCER DISCOVERY (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Klaus P. Hoeflich et al.
CANCER RESEARCH (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Sarat Chandarlapaty
CANCER DISCOVERY (2012)
Receptor tyrosine kinases and their activation in melanoma
David J. Easty et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Visualizing spatiotemporal dynamics of multicellular cell-cycle progression
Asako Sakaue-Sawano et al.
CELL (2008)
分享论文
